drugset / Trial / NCT04877275

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

NCT04877275

Phase 2 Unknown 50 enrolled Chunyan Sun, MD
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-arm that includes two experimental arms,Selinexor(ATG-010) in Combination with Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients.To evaluate efficacy and safety of ATG-010 in combination with chemotherapy in RRMM patients received at least one prior lines of therapy

Timeline

Start
2021-05-21
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject Selinexor Other / unclassified 80 mg Oral
Subject Selinexor Other / unclassified 100 mg Oral
Background Dexamethasone Small molecule 40 mg

Indications